Summary of Alkermes plc Q4 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenues: Nearly $1.5 billion for 2025, a 9% year-over-year increase.

Net Sales:

VIVITROL: $467.9 million

ARISTADA: $370 million

Livaldi: $346.7 million

Adjusted EBITDA: $394 million for the year.

GAAP Net Income: $241.7 million.

Cash Position: $1.3 billion at year-end.

Debt: Entered a $1.525 billion term loan to fund the acquisition of Avadel, expected to be paid down quickly with cash flows.

2Strategic Updates and Business Highlights

Acquisition of Avadel: Completed in February 2026, enhancing Alkermes' entry into the sleep medicine market and adding Loomrise, a sodium oxybate product for narcolepsy.

Elixorexant Development: The orexin candidate is set to enter Phase 3 trials for narcolepsy, following FDA breakthrough therapy designation.

Expansion of Psychiatry Sales Force: Increased engagement with prescribers has driven growth in proprietary products.

Loomrise Performance: Generated approximately $279 million in net sales in 2025, with expectations for continued growth.

3Forward Guidance and Outlook

2026 Revenue Expectations: Projected total revenues between $1.73 billion and $1.84 billion, with proprietary product sales expected to range from $1.52 billion to $1.6 billion.

Adjusted EBITDA Guidance: Estimated between $370 million and $410 million.

R&D and SG&A Expenses: R&D expenses projected at $445 million to $485 million; SG&A expenses expected to be $890 million to $930 million, including one-time transaction costs related to the Avadel acquisition.

4Bad News, Challenges, or Points of Concern

VIVITROL LOE: Anticipated loss of exclusivity in 2027 poses a risk to future revenues.

Increased Costs: Significant increases in R&D and SG&A expenses due to the acquisition and ongoing development programs.

Market Competition: Potential competitive pressures from new entrants in the sleep medicine market, particularly with the anticipated launch of Takeda's oviporexant.

Regulatory Risks: The success of elixorexant and other candidates is contingent on regulatory approvals and market acceptance.

5Notable Q&A Insights

Phase 3 Trial Design: Questions about the AE profile of split dosing for elixorexant were addressed, emphasizing a favorable safety profile.

Integration of Avadel: The integration of the Avadel sales force is expected to yield synergies, although initial overlaps with the psychiatry sales force are limited.

Market Dynamics: Discussions highlighted the potential for both elixorexant and Loomrise to coexist in the market, catering to different patient needs.

Future Studies: Plans to explore the combination of elixorexant and oxybates for certain patients were discussed, focusing on evidence-building for reimbursement purposes. Overall, Alkermes is positioned for growth in 2026 with a strong commercial portfolio and promising pipeline developments, despite facing challenges from market competition and regulatory hurdles.